TRACON Pharmaceuticals, Inc. announced that the US FD) has granted fast track designation for the development of envafolimabf or patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy.
[TRACON Pharmaceuticals, Inc.]